Evonik, to expand biomaterials portfolio has acquired JeNaCell. The German biotech company JeNaCell has developed one of the most innovative biomaterials for medical device technologies. JeNaCell’s product developments are complementary to the portfolio of Evonik’s Health Care business.
- The acquisition expands Evoniks biomaterials portfolio to provide biotechnologically derived cellulose
- The nature-identical material developed by JeNaCell is used in medical technology and dermatology for the treatment of wounds and burns as well as in hydroactive skin care.
- JeNaCell’s portfolio will be integrated into Evonik’s health care business.
The prominent acquisitions and expansion by Evonik are mentioned below:
June 2021: To boost cosmetic delivery systems Evonik announced to acquire the privately owned technology-driven company Infinitec Activos. The Spain based Infinitec Activos focuses on the development and production of novel active delivery systems for cosmetic active ingredient applications.
May 2021: The leading SLS 3D printer manufacturer Farsoon, and chemicals company Evonik announce collaboration on 3D printing materials with higher temperature resistance. The Evonik has tested ready-to-use polymer powder INFINAM® PA 6005 P (polyamide 613) with higher temperature resistance on Farsoon’s ST252P and HT403P series machines.
Feb 2021: To strengthen e-commerce business Evoniks venture capital arm has invested in start-up company chembid. The Oldenburg, Germany based chembid is a worlds largest search engine and market intelligence platform for chemicals.
Dec 2020: To strengthen biodegradable polymers business Evonik announced to acquire the LACTEL from DURECT Corporation for $15 million. The acquisition of the Lactel business will strengthen both innovation growth in the field of Healthcare Solutions and Evoniks position as a globally leading CDMO for drug delivery solutions.
Oct 2020: Evonik announced that Evonik Venture Capital had sold its stake in Synoste Oy to U.S. based Globus Medical. Evoniks four-and-a-half-year partnership helped in the development of Synostes technology for orthopedics and giving Evonik further insights into the medical applications market for its high-performance polymers.
Aug 2020: Evonik is acquiring the Texas based Porocel Group for approximately US$210 million. The acquisition of Porocel accelerates the growth of its catalysts business of Evonik.
May 2020: Evonik announced an exclusive agreement with Glenn Corporation a division of Azelis Americas. As per agreement Glenn will distribute the product protection line by Evoniks Dr. Straetmans brand in the United States.
The Evonik Dr. Straetmans product range includes multifunctional antimicrobials and preservative blends, antioxidants and chelating agents.
February 2020: Evonik had announced the acquisition of Princeton based Wilshire Technologies, a leading supplier of phytochemicals and derivatives to the global cosmetic and pharmaceutical industries. The transaction also includes Wilshire Technologies employees, and cosmetic active ingredients portfolio.
February 2020: Evonik had closed the acquisition of the US company PeroxyChem for US$640 million. PeroxyChem is a leading manufacturer of hydrogen peroxide (H2O2) and peracetic acid (PAA) and is well-positioned in high-margin specialty applications.
Evonik, headquartered at Essen, North Rhine-Westphalia, Germany, is one of the worlds leading specialty chemicals companies. The company is operating in more than 100 countries, and employing approximately 36,000 people across the world. The companys product makes tires fuel-efficient, mattresses more elastic, medications more effective, and animal feeds healthier. Evonik, provides biomaterials for use in medical implant applications.